

KATRD INTERNATIONAL CONFERENCE 2024

The 138th Congress of the Korean Academy of Tuberculosis and Respiratory Diseases

Better Lungs, Better Tomorrow!



| | | |
|------------------|--|--|
| Name | Kim, Song Yee | |
| Country | Republic of Korea | |
| Organization | Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Yonsei University College of Medicine | |
| Current Position | Associate Professor | |

Educational Background

- Mar. 1999 - Feb. 2005 Bachelor Degree,
Yonsei University College of Medicine, Seoul, Korea
- Sep. 2008 - Aug. 2010 Master's Degree of Medicine,
Yonsei University College of Medicine, Seoul, Korea
- Sep. 2011 – Feb. 2014 Doctor's Degree of Medicine
Yonsei University College of Medicine, Seoul, Korea

Professional Experiences

- Mar. 2005 - Feb. 2006 Internship, Severance Hospital,
Yonsei University College of Medicine, Seoul, Korea
- Mar. 2007 - Feb. 2011 Residency, Severance Hospital, Department of Internal Medicine,
Yonsei University College of Medicine, Seoul, Korea
- Mar. 2011~ Feb.2013 Clinical and Research Fellowship, Severance Hospital,
Division of Pulmonology, Department of Internal Medicine,
Yonsei University College of Medicine, Seoul. Korea
- Mar. 2013~Fev.2017 Clinical Assistant Professor, Severance Hospital,
Division of Pulmonology, Department of Internal Medicine,
Yonsei University College of Medicine, Seoul. Korea
- Mar. 2017~Fev 2020 Assistant Professor, Severance Hospital,
Division of Pulmonology, Department of Internal Medicine,
Yonsei University College of Medicine, Seoul. Korea
- Mar.2020~ Associate Professor, Severance Hospital,
Division of Pulmonology, Department of Internal Medicine,
Yonsei University College of Medicine, Seoul. Korea



Professional Organizations

The member of the Korea Academy of Tuberculosis and Respiratory diseases

The member of the Korean Association of Internal Medicine

The member of the Korean Society for Transplantation

Main Scientific Publications

1. The Responses of Multiple Cytokines Following Incubation of Whole Blood from TB Patients, Latently Infected Individuals and Controls with the TB Antigens ESAT-6, CFP-10 and TB7.7. Kim SY, Park MS, Kim YS, Kim SK, Chang J, Lee HJ, Cho SN, Kang YA. *Scand J Immunol.* 2012;76(6):580-
2. Risk factors for occurrence and 30-day mortality for carbapenem-resistant *Acinetobacter baumannii* bacteraemia in an intensive care unit. Kim SY, Jung JY, Kang YA, Lim JE, Kim EY, Lee SK, Park SC, Chung KS, Park BH, Kim YS, Kim SK, Chang J, Park MS. *J Korean Med Sci.* 2012 Aug;27(8):939-47
3. Conversion rates of an interferon- γ release assay and the tuberculin skin test in the serial monitoring of healthcare workers. Kim SY, Park MS, Kim YS, Kim SK, Chang J, Kang YA. *Infection.* 2013 Apr;41(2):511-6.
4. Comparison of the tuberculin skin test and interferon- γ release assay for the diagnosis of latent tuberculosis infection before kidney transplantation. Kim SY, Jung GS, Kim SK, Chang J, Kim MS, Kim YS, Kang YA, Joo DJ. *Infection.* 2013 Feb;41(1):103-10.
5. Increased prevalence of self-reported asthma among Korean adults: an analysis of KNHANES I and IV data. Kim SY, Jung JY, Park MS, Kang YA, Kim EY, Kim SK, Chang J, Kim YS. *Lung.* 2013 Jun;191(3):281-8.
6. Tuberculin skin test and boosted reactions among newly employed healthcare workers: an observational study. Kim SY, Park MS, Kim YS, Kim SK, Chang J, Yong D, Kim HS, Lee K, Kang YA. *PLoS One.* 2013 May 24;8(5):e64563.
7. Standardization of multilocus sequence typing scheme for *Mycobacterium abscessus* and *Mycobacterium massiliense*. Kim SY, Kang YA, Bae IK, Yim JJ, Park MS, Kim YS, Kim SK, Chang J, Jeong SH. *Diagn Microbiol Infect Dis.* 2013 Oct;77(2):143-9
8. The drug susceptibility profile and inducible resistance to macrolides of *Mycobacterium abscessus* and *Mycobacterium massiliense* in Korea. Kim SY, Kim CK, Bae IK, Jeong SH, Yim JJ, Jung JY, Park MS, Kim YS, Kim SK, Chang J, Kang YA. *Diagn Microbiol Infect Dis.* 2015 Feb;81(2):107-
9. The risk factors and characteristics of COPD among never-smokers in Korea: an analysis of KNHANES IV and V. *Lung.* Lee SH, Hwang ED, Lim JE, Moon SW, Kang YA, Jung JY, Pakr MS, Kim SK, Chang J, Kim YS, Kim SY. 2016 Jun;194(3):353-361
10. Prevalence and impact of diabetes mellitus among patients with active pulmonary tuberculosis in South Korea. Lee EH, Lee JM, Kang YA, Leem AY, Kim EY, Jung JY, Park MS, Kim YS, Kim SK, Chang J, Kim SY. *Lung.* 2017 Apr;195(2):209-215
11. Risk factors for *Pneumocystis jirovecii* pneumonia (PJP) in kidney transplantation recipients. Lee SH, Huh KH, Joo DJ, Kim MS, Kim SI, Lee J, Park MS, Kim YS, Kim SK, Chang J, Kim YS, Kim SY. *Sci Rep.* 2017 May 8;7(1):1571.
12. Active Tuberculosis Incidence and Characteristics in Patients Treated with Tumor Necrosis Factor Antagonists According to Latent Tuberculosis Infection. Lee EH, Kang YA, Leem AY, Park MS, Kim YS, Kim SK, Chang J, Kim SY.



SY. Sci Rep. 2017 Jul 25;7(1):6473.

13. Perioperative factors associated with 1-year mortality after lung transplantation: a single-center experience in Korea. Lee SH, Park MS, Song JH, Kim YS, Lee JG, Paik HC, Kim SY. J Thorac Dis. 2017 Oct;9(10):4006-4016
14. Serial testing of healthcare workers for latent tuberculosis infection and long-term follow up for development of active tuberculosis. Park Y, Kim SY, Kim JW, Park MS, Kim YS, Chang J, Kang YA. Plos One 2018 Sep 20;13(9):e0204035.
15. Factors Associated with Lung Function Recovery at the First Year after Lung Transplantation. Yoon BR, Park JE, Kim CY, Park MS, Kim YS, Chung KS, Song JH, Paik HC, Lee JG, Kim SY. Yonsei Med J. 2018 Nov;59(9):1088-1095
16. Prevalence of pre-transplant anti-HLA antibodies and their impact on outcomes in lung transplant recipients. Park JE, Kim CY, Park MS, Song JH, Kim YS, Lee JG, Paik HC, Kim SY. BMC Pulm Med. 2018 Mar 12;18(1):45
17. Urine IP-10 as a biomarker of therapeutic response in patients with active pulmonary tuberculosis. Kim SY, Kim J, Kim DR, Kang YA, Bong S, Lee J, Kim S, Lee NS, Sim B, Cho SN, Kim YS, Lee Hj. BMC Infect Dis. 2018;18(1):240;1471-2334
18. Thoracic skeletal muscle quantification: low muscle mass is related with worse prognosis in idiopathic pulmonary fibrosis patients. Moon SW, Choi JS, Lee SH, Jung KS, Jung JY, Kang YA, Park MS, Kim YS, Chang J, Kim SY. Respir Res. 2019;20(1):35;1465-993X
19. Prognostic impact of the ratio of the main pulmonary artery to that of the aorta on chest computed tomography in patients with idiopathic pulmonary fibrosis. Choi JS, Lee SH, Leem AY, Song JH, Chung KS, Jung JY, Kang YA, Park MS, Kim YS, Chang J, Kim SY. BMC Pulm Med. 2019;19(1):81;1471-2466
20. Panel-reactive and donor-specific antibodies before lung transplantation can affect the outcomes of Korean lung transplantation patients. Moon SW, Park MS, Lee JG, Paik HC, Kim YT, Lee HJ, Park S, Choi SM, Kim, Cho WH, Yeo HJ, Park SI, Choi SH, Hong SB, Shim TS, Jo KW, Jeon K, Jeong BH, Kim SY, Korean Organ Transplantation Registry Study Group. Yonsei Med J. 2020 Jul 1; 61(7): 606–613.
21. Risk Factors for Cytomegalovirus Reactivation in Lung Transplant Recipients. Kwak SH, Lee SH, Park MS, Jeong SJ, Lee JG, Paik HC, Kim YS, Chang J, Kim SY. Lung. 2020 Oct;198(5):829-838.
22. Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: real world experience from a tertiary university hospital. Song MJ , Moon SW ,Choi JS , Lee SH, Lee SH, Chung KS, Jung JY, Kang YA, Park MS, Kim YS, Chang J, Kim SY. Sci Rep. 2020 Dec 4;10(1):21218
23. Effectiveness of pirfenidone in idiopathic pulmonary fibrosis according to the autoantibody status: a retrospective cohort study. Song MJ, Lee SH, Jung JY, Kang YA, Park MS, Kim YS, Chang J, Kim SY. BMC Pulm Med 2021;21:145
24. Reference values of skeletal muscle area for diagnosis of sarcopenia using chest computed tomography in Asian general population. Moon SW, Lee SH, Woo A, Leem AY,,Lee SH,Chung KS, Kim EY, Jung JY, Kang YA, Park MS, Kim YS, Kim CO, Kim SY. J Cachexia Sarcopenia Muscle. 2022;13:955-965.
25. COVID-19 Vaccine-Associated Pneumonitis in the Republic of Korea: A Nationwide Multicenter Survey. Yoo H, Kim SY, Park MS, Jeong SH, Park SW, Lee HL, Lee HK, Yang SH, Jegal Y, Yoo JW, Lee J, Kang HK, Choi SM, Park J, Kim YW, Song JW, Park JH, ChoiWI, Choi HS, Park C, Park JW, Chung MP. J Korean Med Sci. 2023 Apr 10; 38(14): e106.
26. Repositioning of ezetimibe for the treatment of idiopathic pulmonary fibrosis. Lee CH, Kwak SH, Han J, Shin JH, Yoo B, Lee YS, Park SJ, Lim BJ, Lee JG, Kim YS, Kim SY, Bae SH. Eur Respir J. 2024 May 16;63(5):2300580